Euclises Pharmaceuticals is developing novel enzyme (COX-2) inhibitors designed to increase the effectiveness of chemotherapy safely
Total raised: $3.3M
Investors 5
| Date | Name | Website |
| 10.01.2024 | Cultivatio... | cultivatio... |
| - | iSelect Fu... | iselectfun... |
| - | Missouri T... | missourite... |
| - | Lagomaj Ca... | lagomaj.co... |
| - | Argonautic | argonautic... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 07.04.2015 | Series A | $2M | - |
| 09.09.2014 | Series A | $1.3M | - |
Mentions in press and media 12
| Date | Title | Description |
| 19.01.2017 | John Talley Turns His Attention to Cancer Therapy | For Euclises, it’s simple. Without the work of John Talley, Ph.D., the world would not have Celebrex®, the blockbuster arthritis treatment that has generated in excess of $3.5 billion in sales for Pfizer. Or Dynastat®, an injectable COX-2 i... |
| 09.12.2015 | Euclises Pharmaceuticals, Inc. Receives Notice of Patent Allowance from European Patent Office for New Class of Compounds for Treatment of Cancer, Pain and Inflammation | ST. LOUIS–(BUSINESS WIRE)–December 9, 2015– Euclises Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel COX-2 inhibitors for use in treating certain cancers, pain and inflammation, has recei... |
| 20.10.2015 | The New American Entrepreneur – Euclises | Euclises is drug discovery and development company targeting some of the deadliest cancers out there—cancers that combine to cause over 200,000 fatalities each year in the U.S. alone. By offering new treatment options for cancer patients su... |
| 20.10.2015 | A Q&A session with Euclises’ John Talley | [iSelect] You have the honorable position of being one of the leading medicinal chemists in the world. [John] It’s funny. I don’t think of myself that way at all. I’ve had the great fortune to work with really great people on really good pr... |
| 07.04.2015 | Euclises Pharmaceuticals Completes Nearly $2M Series A Funding | Euclises Pharmaceuticals, Inc., a a St. Louis-based biotechnology company developing third-generation COX-2 inhibitors, completed its nearly $2m Series A funding round. Backers included Cultivation Capital, St. Louis Arch Angels, and BioGen... |
| 07.04.2015 | Euclises Completes Financing Round | ST. LOUIS–(BUSINESS WIRE)–April 7, 2015– Euclises Pharmaceuticals, Inc., a pharmaceutical company developing third-generation COX-2 inhibitors, today announced additional investments that complete its Series A round. The additional financin... |
| 27.01.2015 | Euclises Announces Appointment of Bobby Sandage as New CEO | Development Experience to Drive Entry of Novel COX-2 Inhibitors into Clinical Trials for Cancer ST. LOUIS–(BUSINESS WIRE)–January 27, 2015– Euclises Pharmaceuticals, Inc., a biotechnology company developing novel cyclooxygenase-2 (COX-2) in... |
| 20.01.2015 | BioTech Selection Committee: Bobby Sandage | Spotlight: Selection Committee Member A Brief Background: Bobby W. Sandage, Jr., Ph.D. has 34 years of experience in the pharmaceutical and biotech industry and was recently appointed President and CEO of Euclises Pharmaceuticals a St. Loui... |
| 03.12.2014 | Euclises Announces Development Agreement with GIBH | Collaboration to Accelerate Development of Novel COX-2 Inhibitors for Cancer ST. LOUIS–(BUSINESS WIRE)–December 3, 2014– Euclises Pharmaceuticals, Inc., a biotechnology company developing novel cyclooxygenase-2 (COX-2) inhibitors for the tr... |
| 09.09.2014 | Euclises Pharmaceuticals Closes $1.3M Series A Financing | Euclises Pharmaceuticals, Inc., a St. Louis-based biotechnology company developing novel COX-2 inhibitors for the treatment of cancer, closed $1.3m Series A financing. The round was led by Cultivation Capital, with participation from BioGen... |
Show more